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egression of Atherosclerosis
ith Therapeutic Antibodies
ipe Cleaner or Pipe Dream?*
eoffrey S. Ginsburg, MD, PHD, FACC
urham, North Carolina
xidized low-density lipoprotein (oxLDL) is an immuno-
en that plays an important role in the initiation and
rogression of atherosclerosis (1). Active immunization with
xLDL in model systems prone to atherosclerosis results in a
eightened adaptive immune response and protection against
esion formation (2). Indeed, in vitro oxidation of low-density
ipoprotein (LDL) results in multiple oxidation-specific
pitopes (3,4) in the peptide sequences of its protein com-
onent, apolipoprotein B (apoB), and in its phospholipid
oieties. Together, these are highly immunogenic and can
e used to generate immunoglobulin (Ig) G antibodies that
n turn lead to inhibition of atherosclerosis in the murine
DL receptor knockout and apolipoprotein E knockout
ApoE/) models of atherosclerosis. It has been suggested
hat anti-oxLDL antibodies might possess pathogenic as
ell as protective effects (5). The pathogenic effects of
nti-oxLDL antibodies is supported by observations of
levated IgG seen in lesions (6) in the sera of patients with
oronary disease (7,8), peripheral vascular disease (9), and
ith syndromes associated with accelerated atherosclerosis
uch as hypertension, diabetes, and immune-mediated dis-
ases (e.g., rheumatoid arthritis, systemic lupus erythema-
osis) (10,11). However, others have speculated that the
See page 2313
igher levels of anti-oxLDL antibodies, in particular IgM
utoantibodies, observed in children compared with levels in
dults might serve a protective purpose. Furthermore, other
tudies have demonstrated an inverse association of intimal
edia thickness in the carotid arteries with anti-oxLDL
ntibody levels in serum (12). Several monoclonal antibod-
es (mAbs) have been developed that bind epitopes on
xLDL and are used to assay oxLDL levels in plasma or
n vascular lesions. Assays using these antibodies have
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From the Institute for Genome Sciences and Policy, Duke University, Durham,
orth Carolina.een developed as probes to cultivate a greater under-
tanding of the clinical utility of anti-oxLDL as a
irculating biomarker for atherosclerosis (13).
Based on observations that a large number of malondial-
ehyde-modified sequences in apoB are recognized in hu-
an plasma and that immunization of ApoE/ mice with
hese peptides resulted in inhibition of atherosclerosis de-
elopment, Schiopu et al. (14) developed a series of mAbs
gainst apoB peptides 661 to 680. These antibodies, when
njected into the ApoE/ mice, reduced the extent of
therosclerosis development as well as the plaque content of
xLDL epitopes (14), providing support for the hypothesis
hat passive immunity with anti-oxLDLmight be protective
gainst atherosclerosis. These results were observed despite
he fact that these mice developed significant titers of
ntihuman antibodies. Other groups have confirmed and
xtended this finding using alternative antibody prepara-
ions against different epitopes on oxLDL (15,16). In the
urrent issue of the Journal, this group has extended their
ork to show that anti-oxLDL antibodies can induce
egression of established atherosclerosis in a mouse model
17). The effects on pre-existing vascular atherosclerosis of
ecombinant IgG antibodies against the oxLDL apoB
pitope between amino acids 661 and 680 were assessed in
n experimental model of atherosclerosis. The administra-
ion of 3 weekly doses of the antibodies led to a rapid and
ignificant regression of existing lesions. This observation, if
onfirmed, implies that passive immunity could have an
mportant role in ameliorating established atherosclerotic
ascular disease.
Immune-mediated therapies have existed for more than
00 years with passive antibody therapy, or “serum therapy,”
eing a mainstay of treatment for pneumonia, meningitis,
nd a variety of other infectious diseases (18). These crude
eterologous extracts from sera were fraught with variability
n efficacy and risk of allergic reactions and serum sickness.
oday antibody purification, hybridoma technology, and
he development of mouse–human chimeric and humanized
Abs have markedly improved the specificity and reduced
he potential for toxicity from mAb therapies. The latter
ave provided for reduced immunogenicity and longer
alf-lives, issues that have plagued many biologic candidates
or human use. More recently phage display, the ability to
anipulate various antibody regions and enhance function-
lity, and the ability to express human antibodies in different
pecies (even in plants) have led to a reduction in both the
oxicity and variability seen in antibody preparations of the
ast. Over the past 2 decades, more than 20 antibodies have
een approved by the Food and Drug Administration, all of
hich were monoclonal. The vast majority of these were
eveloped with a therapeutic goal of inhibition of host cell
unction targeting cellular antigens to interfere with cell
unction and achieve a therapeutic effect. Abciximab, a Fab
ragment preparation of the mouse–human chimeric anti-
ody c7E3 with specificity for glycoprotein IIb/IIIa in
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Editorial Comment December 11, 2007:2319–21uman platelets, is the only antibody therapeutic approved
or human use clinically in cardiovascular disease in the
etting of acute myocardial infarction and high-risk percu-
aneous coronary interventions. Despite these successes and
he compelling data from animal models described in this
ssue and elsewhere, the path to therapeutic antibody
herapy for regression of established atherosclerosis will be
rduous. There are several major issues that must be addressed
or these achievements to translate into clinical utility.
hould an Anti-oxLDL Be Polyclonal or Monoclonal?
he major question here is whether the therapeutic target of
xidation of LDL is a single epitope or multiple epitopes.
everal oxidation-specific epitopes on LDL exist, including
hose on apoB and its lipids; however, it is uncertain if a
ingle therapeutic antibody will be sufficient to result in
linically significant regression of disease. It may be that in
umans a combination of mAbs will be required to provide
diversity of biologic function. Thus, for any individual
atient, the activity of a polyclonal preparation will reside in
subfraction of the total Ig preparation, therefore requiring
arge amounts of protein to achieve the desired effect and
xposing patients to higher probabilities of toxicity (dis-
ussed later) and higher costs associated with preparation of Ig.
hat About Antibody Specificity?
major advantage of antibody therapeutics is the potential
o design therapies with great specificity for a particular cell
ype or functional receptor. Whether this advantage can be
chieved with anti-oxLDL antibodies is difficult to ascertain
t this time. For example, how antigenically diverse is
xLDL in humans? Are all epitopes present in susceptible
ndividuals or do individuals exhibit temporal changes in the
xLDL epitopes that are expressed? Are these epitopes
resent in normal tissues, and if so, what are the conse-
uences of exposure to them in this respect? Clearly,
dditional experiments are required to address these issues.
hould the Therapeutic Antibody
e Heterologous or Homologous?
chiopu et al. (14,17) used a recombinant human IgG that,
n mice, results in significant titers of antihuman antibodies.
n humans, a human antibody preparation would be a very
easonable approach to minimize the potential of immune-
ediated sensitivity reactions (e.g., human antimouse anti-
odies) seen in heterologous antibody products. However,
ven humanized therapeutic antibodies have resulted in
uman antichimeric and human antihuman neutralizing
ntibodies that have limited therapeutic effectiveness or
nduced adverse reactions in humans. Although the use of
omologous antibodies is expected to come with a reduced
isk of toxicologic side effects, these reactions would need to
e extensively studied in the first human studies using this
pproach. In addition, the reduction in the likelihood of
ypersensitivity afforded by a human antibody may carry an pdditional financial burden. Given the fact that most human
reparations of antibody may be 100-fold greater in cost
han heterologous preparations plus the likelihood that
nti-oxLDL therapy would be a lifelong treatment, cost is a
ignificant factor.
hould an Intact Antibody
r a Fab Fragment Be Used
nd What Dose Would Be Optimal?
ab fragments have the advantage of lower immunogenicity
nd shorter half-lives. The half-life, dose, and dose interval
ill need to be established in humans to carry out a
uccessful clinical trial. The antibody used by Schiopu et al.
14,17) is an intact human IgG with a short half-life,
videnced by the fact that it is absent from the circulation of
ice within 2 weeks. The utility of the murine data for
osing in humans is likely to be minimal; therefore, human
tudies and empiric dosing studies will need to be carried
ut to ascertain the appropriate dosing schedules in humans.
major issue that will need to be resolved in future studies
f this approach is the extent to which the disease progresses
ollowing cessation of any antibody therapy and thus how
ong after therapy would it need to be re-initiated, assuming
he disease returns. In the current study (17), animals were
acrificed just 2 weeks following the last of 3 doses, which is
ot a long enough duration to assist us in answering this
mportant question.
ow Would Antibody Therapy
e Combined With Current Drugs
r Diet Therapies for Coronary Artery Disease?
or an antibody therapy approach to succeed clinically, it
ust have superior efficacy and/or lower toxicity than
xisting therapies when used alone or in combination with
xisting therapies. Schiopu et al. (17) switched from an
therogenic to a normal chow diet in their murine studies.
he next series of studies on regression should consider the
se of these antibodies adjunctively with the standard
herapies for atherosclerosis. Moreover, we need to under-
tand the utility of this approach in the setting of a proathero-
enic environment, which unfortunately is the world in which
e live.
Thus, although the murine studies presented in this issue
f the Journal provide an important “proof of concept” that
egression of atherosclerosis with an antibody therapeutic is
easible in mice, the hurdles to developing a human thera-
eutic for regression of disease are significant. Clearly, more
tudies are needed to identify the dominant antigens
ediating atherosclerosis. Further, human validation and
ong-term administration may be limited by immune
eactions to the active agent. Thus, although the concept
f antibody-mediated regression of atherosclerosis is
ttractive, the formidable challenges that must be over-
ome are significant for this to remain more than just a
ipe dream.
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